Towards Healthcare’s IVD Competitive Quadrant Analysis Reveals Industry Leaders

For healthcare leaders, selecting a diagnostic partner involves more than comparing instruments and test menus. The decision can affect clinical development, laboratory efficiency, commercialization, partnerships and long-term business performance.

Towards Healthcare’s Competitive Intelligence (CI) and Competitive Strength Index (CSI) Framework evaluates 15 IVD companies across execution capability, future readiness and relevant-market revenue. Its Competitive Quadrant helps decision-makers assess competitive strengths, identify potential gaps and support partnership, investment and portfolio decisions.

Towards Healthcare’s IVD Competitive Quadrant Analysis

The framework evaluates companies across two dimensions:

• Execution Capability (X-axis): Assesses competitive execution and current capabilities.

• Future Readiness (Y-axis): Assesses positioning for evolving technologies and diagnostic requirements.

The execution median is 4.27, and the future-readiness median is 4.29, with both dimensions scored out of 5. Bubble size represents USD-equivalent relevant-market revenue, while CSI provides a consolidated view of competitive strength.

The analysis identifies four quadrants: Visionary Leaders, Dynamic Differentiators, Innovators and Emerging Companies. Each offers a different perspective on competitive positioning and potential strategic opportunities.

Visionary Leaders: Strong Execution and Future Readiness

Visionary Leaders score above the median on both dimensions, combining established capabilities with strong future readiness. They provide useful benchmarks for pharmaceutical companies, healthcare organizations and investors assessing potential partners.

Roche Sets the Benchmark

F. Hoffmann-La Roche Ltd records the highest CSI at 4.74, with execution of 4.74, future readiness of 4.75 and relevant-market revenue of $16,660 million.

Its position reflects strong scores across both dimensions and the largest revenue value in this peer group. For decision-makers, Roche provides a benchmark for evaluating portfolio strength, execution and commercial scale.

However, the best partner still depends on the intended application, technical requirements and strategic objectives.

Danaher and Abbott Maintain Strong Competitive Positions

Danaher's execution score is higher, while Abbott's future-readiness score is higher. This distinction shows why pharmaceutical leaders should examine individual capabilities rather than rely on overall rankings alone.

Specialized Capabilities Add Strength to the Quadrant

These results demonstrate that companies can achieve strong positions through different combinations of capabilities.

For pharmaceutical organizations evaluating diagnostic partnerships, the next step is to examine assay requirements, regulatory experience, technical compatibility and the ability to support clinical or commercial objectives.

Strategic takeaway: Visionary Leaders provide strong benchmarks, but application-level fit and partnership requirements should determine the final choice.

Dynamic Differentiators: Strong Execution With Future-Readiness Gaps

Dynamic Differentiators demonstrate strong execution but score below the future-readiness median. Their positioning encourages decision-makers to assess whether current capabilities align with evolving diagnostic requirements.

Siemens Healthineers

Siemens Healthineers records execution of 4.42, future readiness of 4.18 and a CSI of 4.38. Its relevant-market revenue is $4,907 million.

QuidelOrtho

QuidelOrtho records execution of 4.27, future readiness of 4.13 and a CSI of 4.26. Its relevant-market revenue is $2,730 million.

The execution score sits at the stated median, while future readiness is below it. This makes product-level assessment important when considering partnerships or supplier relationships.

Contact our Analyst Today: https://www.towardshealthcare.com/contact-us

What This Quadrant Means for Decision-Makers

This quadrant helps organizations separate current execution strength from future preparedness.

Diagnostic manufacturers can assess investment and technology priorities, while pharmaceutical leaders can examine whether potential partners can support evolving assay, clinical and commercial requirements.

Strategic takeaway: Strong execution matters, but long-term partner selection should also consider future capabilities, product fit and the evidence supporting a proposed collaboration.

Innovators: Future Readiness Above the Benchmark

Innovators score above the future-readiness median but below the execution median. This positioning can help decision-makers identify companies whose capabilities merit closer investigation.

QIAGEN

QIAGEN records future readiness of 4.43, execution of 3.94 and a CSI of 4.13. Its relevant-market revenue is $803 million.

Its future-readiness score stands above the framework median despite a lower execution score. For potential partners, the priority is to validate relevant technologies, regulatory status, technical compatibility and commercialization requirements.

DiaSorin

DiaSorin records future readiness of 4.31, execution of 3.84 and a CSI of 4.02. Its relevant-market revenue is $1,349 million.

Its positioning provides a starting point for assessing whether its capabilities align with a particular diagnostic application or partnership objective.

Why Innovators Deserve a Separate Assessment

Revenue scale and future readiness measure different aspects of competitive positioning. A company with lower revenue may still be relevant when its capabilities fit a specialized clinical or technical requirement.

For pharmaceutical leaders, this can broaden partnership screening beyond the largest suppliers. For investors and diagnostic manufacturers, it can highlight areas for further investigation into commercialization, execution and strategic growth.

Strategic takeaway: Evaluate innovators on specific capabilities and their relevance to the intended opportunity, not on quadrant position alone.

Emerging Companies: Identifying Competitive Gaps and Strategic Priorities

Emerging Companies fall below the framework median on both execution and future readiness. This signals the need for closer assessment, not an automatic conclusion that these companies lack valuable capabilities.

Hologic and Werfen

Hologic records execution of 3.91, future readiness of 4.15 and a CSI of 4.03. Its relevant-market revenue is $1,827 million.

Werfen records execution of 4.04, future readiness of 4.16 and a CSI of 4.12. Its relevant-market revenue is $2,405 million.

Their scores can help buyers identify questions for further evaluation, including product suitability, technical capabilities, regulatory support and commercial requirements.

BD and Revvity

Becton, Dickinson and Company (BD) records execution of 4.13, future readiness of 4.20 and a CSI of 4.19. Its relevant-market revenue is $1,838 million.

Revvity records execution of 4.05, future readiness of 4.20 and a CSI of 4.13. Its relevant-market revenue is $1,425 million.

Both companies sit below the future-readiness median despite having relatively strong scores within their own profiles. Their positioning reinforces the importance of examining each dimension separately.

Bio-Rad Laboratories

Bio-Rad Laboratories records execution of 3.91, future readiness of 3.78 and a CSI of 3.92. Its relevant-market revenue is $1,562 million.

Within this peer group, Bio-Rad has the lowest CSI and future-readiness score. This makes its positioning relevant for further assessment of competitive capabilities and strategic priorities.

However, these scores reflect the selected framework, not a complete judgment of the company's overall business quality or future potential.

Emerging Companies Comparison

Turning the Quadrant Into Action

Healthcare organizations can use this quadrant to identify areas for further due diligence. Diagnostic manufacturers can assess capability gaps, while investors can investigate strategic fit, competitive positioning and potential opportunities.

Strategic takeaway: A lower quadrant position should prompt targeted investigation into capabilities and fit, rather than automatic rejection.

What the CSI Scores Reveal About Competitive Strength

The CSI provides a consolidated view of the companies assessed.

Roche records 4.74, followed by Danaher at 4.66 and Abbott at 4.58. bioMérieux records 4.45, while Siemens Healthineers records 4.38.

CSI Comparison

However, a consolidated score can conceal important differences. Abbott scores higher than Danaher on future readiness, while Danaher scores higher on execution. QIAGEN and DiaSorin also score above the future-readiness median despite lower execution scores.

For pharmaceutical companies, the most relevant partner may be the one that meets specific clinical, technical and regulatory requirements. Laboratory networks may prioritize workflow compatibility and service support, while investors may focus on commercial scale and strategic positioning.

The CSI should therefore support, rather than replace, application-specific assessment and due diligence.

Relevant-Market Revenue Adds Another Layer to the Analysis

Bubble size represents USD-equivalent relevant-market revenue, adding commercial scale to the competitive comparison.

Roche records $16,660 million, followed by Danaher at $9,941 million and Abbott at $8,937 million. QIAGEN records $803 million, the lowest revenue value in this peer group.

Revenue provides context about relative scale, but it does not independently establish innovation, technical suitability or partnership value. A large supplier may suit a broad relationship, while a specialized company may better fit a defined diagnostic requirement.

The figures should also be checked for comparable scope and reporting periods before formal financial decisions. Here, they serve as the stated bubble-size basis, not a complete assessment of company financial performance.

What Pharmaceutical and Healthcare Leaders Should Do With These Findings

The quadrant becomes more valuable when it informs a specific business decision.

Why Towards Healthcare's Competitive Quadrant Analysis Matters

A competitor list identifies the players. A structured quadrant helps decision-makers understand how those companies differ and which deserve closer attention.

Towards Healthcare's CI and CSI Framework connects execution capability, future readiness and relevant-market revenue to support consistent competitive assessment. It helps leaders move from general competitor awareness toward more focused partnership, investment and commercial decisions.

The framework works best as the starting point for a broader process: identify relevant companies, assess their capabilities, validate the evidence and connect findings to business objectives.

How Towards Healthcare Supports Strategic Decisions

Towards Healthcare supports pharmaceutical, biotechnology, medical device and healthcare organizations with strategic intelligence, customized analysis and business consulting.

Our support includes:

• Complete Master Dataset: Structured company, product and competitive information for analysis and planning.

• Competitive Quadrant: Comparative assessment across dimensions relevant to your business objectives.

• Customized Dashboard: Tailored intelligence for ongoing monitoring and decision-making.

• Competitor Tracking: Monitoring company developments, portfolio changes and strategic activity.

• Buyer Identification: Identifying relevant organizations, decision-makers and potential business relationships.

• GTM Strategy: Supporting product positioning, target-segment assessment and geographic priorities.

• Strategic Consulting: Evaluating competitive strengths, capability gaps, partnership options and business opportunities.

For leaders evaluating IVD companies, the key question is not simply who scores highest. It is which capabilities matter most, which companies fit the requirement and where further intelligence can improve the decision.

Towards Healthcare helps turn competitive intelligence into actionable direction for partnership evaluation, investment screening, portfolio prioritization and commercial strategy.

If your organization is assessing IVD competitors, seeking diagnostic partners or evaluating expansion opportunities, Towards Healthcare can support a focused analysis aligned with your business objectives.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected] 

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com 

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium